Another phase II trial that investigated the efficacy of neoadjuvant lapatinib plus capecitabine plus oxaliplatin in HER2-positive GC patients with liver metastasis has been undertaken (NCT02015169) [25]. This evidence concerns the gene ERBB2 and gastric cancer.